

04-23-2002

Form PTO-1595

(Rev. 03/01)

OMB No. 0651-0027 (exp. 5/31/2002)

Tab settings ⇌ ⇌ ⇌ ▼



102064799

T

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

MMC/GATX Partnership No. 1

4-23-02

Additional name(s) of conveying party(ies) attached? ☒ Yes ☐ No

3. Nature of conveyance:

- ☐ Assignment ☐ Merger
- ☐ Security Agreement ☐ Change of Name
- ☒ Other Termination of Security Interest

4/15/2002

Execution Date: _____

2. Name and address of receiving party(ies)

Name: Adeza Biomedical Corporation

Internal Address: _____

Street Address: 1240 E/ko Drive

City: Sunnyvale State: CA Zip: 94089

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s) See attached
scheduleB. Patent No.(s) See attached
scheduleAdditional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: MMC/GATX Partnership No. 1

Internal Address: c/o GATX Ventures, Inc.

ATTN: Legal Department

Street Address: 3687 Mt. Diablo Blvd.,

Suite 200

City: Lafayette State: CA Zip: 94549

6. Total number of applications and patents involved: 24

7. Total fee (37 CFR 3.41).....\$ 960.00

- ☐ Enclosed
- ☐ Authorized to be charged to deposit account

8. Deposit account number:

DO NOT USE THIS SPACE

9. Signature.

Maureen C. Dellinger, Assoc. Counsel
Name of Person SigningMaureen C. Dellinger
SignatureApril 18, 2002
Date

Total number of pages including cover sheet, attachments, and documents: 7

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

04/24/2002 6TON11

00000034 5281522

960.00 OP

01 FC:581

PATENT
REEL: 012802 FRAME: 0856

1. Additional names(s) of conveying party(ies):

Transamerica Business Credit Corporation
76 Batterson Park Road
Farmington, CT 06032

SCHEDULE 1-A TO GRANT OF SECURITY INTEREST

PATENTS

Patent	Registration Number	Registration Date
REAGENTS AND KITS FOR DETERMINATION OF FIBRONECTIN IN A VAGINAL SAMPLE	5,281,522	January 25, 1994
SAMPLE COLLECTION AND TRANSPORT FLUID COMPOSITION	4,919,889	April 24, 1990
PRETERM LABOR AND MEMBRANE RUPTURE TEST	5,096,830	March 17, 1992
SCREENING METHOD FOR IDENTIFYING WOMEN AT INCREASED RISK FOR IMMINENT DELIVERY	5,468,619	November 21, 1995
SCREENING METHOD FOR IDENTIFYING WOMEN AT RISK FOR IMMINENT DELIVERY	5,516,702	May 14, 1996 (priority date 11/06/91)
ECTOPIC PREGNANCY TEST	5,236,846	August 17, 1993 (priority date 11/18/88)
FETAL FIBRONECTIN PREGNANCY TEST	5,185,270	February 9, 1993
EX VIVO PRODUCT OF CONCEPTION TEST TO DETERMINE ABORTION	5,223,440	June 29, 1993
FETAL CELL SEPARATION AND TESTING	4,675,286	January 23, 1997
PREGNANCY INDUCED HYPERTENSION AND ECLAMPSIA IMMUNOASSAY AND REAGENTS	5,079,171	January 7, 1992
MONOCLONAL ANITBODY DEFINING ONCOFETAL STRUCTURE OF FIBRONECTIN	4,894,326	January 16, 1990

ONCOFETAL STRUCTURE OF
FIBRONECTIN

5,243,029

September 7, 1993

DETERMINATION OF ENDOMETRIAL
RECEPTIVITY TOWARD EMBRYO
IMPLANTATION

5,279,941

January 18, 1994

$\alpha_v\beta_3$ INTEGRIN AS A PREDICTOR OF
ENDOMETRIOSIS

5,478,725

December 26, 1995

SCHEDULE 1-B TO GRANT OF SECURITY INTEREST

PATENT APPLICATIONS

Patent Application	Application Number	Application Date
ASSAY METHOD TO RULE OUT RUPTURE OF MEMBRANE IN WOMEN AT RISK FOR IMMINENT DELIVERY	08/935,162	September 22, 1997 (priority date 01/22/93)
POINT OF CARE DIAGNOSTIC SYSTEMS	09/017,901	February 3, 1998
POINT OF CARE DIAGNOSTIC SYSTEMS	09/063,497	April 20, 1998
POINT OF CARE DIAGNOSTIC READER (DESIGN)	29/086781	April 20, 1998
POINT OF CARE DIAGNOSTIC DEVICE (DESIGN)	29/086799	April 20, 1998
METHOD FOR DEVELOPING MEDICAL & BIOCHEMICAL DIAGNOSTIC TESTS USING NEURAL NETWORKS	08/798,306	February 7, 1997 (priority date 2/9/96)
METHOD FOR DEVELOPING MEDICAL & BIOCHEMICAL DIAGNOSTIC TESTS USING NEURAL NETWORKS	08/912,133	August 14, 1997
METHOD FOR DEVELOPING MEDICAL & BIOCHEMICAL DIAGNOSTIC TESTS USING NEURAL NETWORKS	09/134,636	August 14, 1997
METHOD FOR DEVELOPING MEDICAL & BIOCHEMICAL DIAGNOSTIC TESTS USING NEURAL NETWORKS	NOT AVAILABLE	December 12, 1998
DETERMINATION OF ENDOMETRIAL RECEPTIVITY TOWARD EMBRYO IMPLANTATION	08/756,211	November 25, 1996
DETERMINATION OF ENDOMETRIAL RECEPTIVITY TOWARD EMBRYO IMPLANTATION	09/149,183	September 8, 1998

**TERMINATION
OF
SECURITY INTEREST IN PATENTS**

This Termination of Security Interest in Patents (the "Termination") is executed on behalf of MMC/GATX PARTNERSHIP NO. I and TRANSAMERICA BUSINESS CREDIT CORPORATION, as Secured Parties (the "Lenders"), in favor of Adeza Biomedical Corporation, a Delaware corporation (the "Debtor"), and is effective as of April 15, 2002.

RECITALS

A. Debtor and the Secured Parties entered into a certain Loan and Security Agreement, dated as of March 19, 1999 (the "Agreement").

B. The Grant of Security Interest in Patents, relating to the Agreement, was filed with the Patent and Trademark Office on March 26, 1999, at Reel/Frame 9845/0090.

C. Debtor has repaid all amounts due under the Agreement.

The Secured Parties therefore expressly terminate their security interest in the Collateral, including without limitation, the patents and patent applications listed on Schedule 1-A and 1-B attached hereto.

IN WITNESS WHEREOF, this Termination is executed as of the date first above written.

MMC/GATX PARTNERSHIP NO. I, as Secured Party
and Lender

By: GATX Financial Corporation (f/k/a GATX Capital
Corporation), its general partner

By: Patricia W. Leicher

Name: Patricia W. Leicher

Title: Vice President

**TRANSAMERICA BUSINESS CREDIT
CORPORATION**, as Secured Party and Lender

By: _____

Name: _____

Title: _____

TERMINATION

OF

SECURITY INTEREST IN PATENTS

This Termination of Security Interest in Patents (the "Termination") is executed on behalf of MMC/GATX PARTNERSHIP NO. I and TRANSAMERICA BUSINESS CREDIT CORPORATION, as Secured Parties (the "Lenders"), in favor of Adeza Biomedical Corporation, a Delaware corporation (the "Debtor"), and is effective as of April 15, 2002.

RECITALS

A. Debtor and the Secured Parties entered into a certain Loan and Security Agreement, dated as of March 19, 1999 (the "Agreement").

B. The Grant of Security Interest in Patents, relating to the Agreement, was filed with the Patent and Trademark Office on March 26, 1999, at Reel/Frame 9845/0090.

C. Debtor has repaid all amounts due under the Agreement.

The Secured Parties therefore expressly terminate their security interest in the Collateral, including without limitation, the patents and patent applications listed on Schedule 1-A and 1-B attached hereto.

IN WITNESS WHEREOF, this Termination is executed as of the date first above written.

MMC/GATX PARTNERSHIP NO. I, as Secured Party
and Lender


By: GATX Financial Corporation (f/k/a GATX Capital
Corporation), its general partner

By: _____

Name: _____

Title: _____

TRANSAMERICA BUSINESS CREDIT
CORPORATION, as Secured Party and Lender

By: 

Name: Allen M. Sailer

Title: Sr. Vice President